| Name | Title | Contact Details |
|---|
Gallini S.R.L. is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pulse Biosciences is a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform. The Company`s CellFX NPS platform provides a novel, precise, non-thermal, treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing acellular tissue. NPS`s unique mechanism of action disrupts the functions of internal cell structures while maintaining the outer cell membrane initiating a cascade of events within the cell that results in regulated cell death.
Creating detection devices that increase productivity and save lives. Based in Boulder, CO the company integrates innovative technologies in various device platforms through strategic partnerships, licensing agreements and acquisitions. Currently we are pilot testing with international employers our first patented and proprietary device SOBRCheck, a non-invasive, touch-based identity verification and alcohol detection solution.
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.